JP7612658B2 - 抗ms4a4a抗体、及びその使用方法 - Google Patents

抗ms4a4a抗体、及びその使用方法 Download PDF

Info

Publication number
JP7612658B2
JP7612658B2 JP2022506146A JP2022506146A JP7612658B2 JP 7612658 B2 JP7612658 B2 JP 7612658B2 JP 2022506146 A JP2022506146 A JP 2022506146A JP 2022506146 A JP2022506146 A JP 2022506146A JP 7612658 B2 JP7612658 B2 JP 7612658B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antibody
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022506146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542964A (ja
JP2022542964A5 (cg-RX-API-DMAC7.html
Inventor
ジョンフン スン,
ウェイ-シェン ホ,
ムハンマド エー. アルハワグリ,
フィリップ リン コン,
エルヴェ リン,
フア ロン,
カルパガム スリニバサン,
アナンヤ ミトラ,
ダニエル ピー. バーミンガム,
クラウス-ディーター ヘーガー,
サンティアゴ ビベロス サラザー,
フランチェスカ チグナレッラ,
イラリア タッシ,
ティナ シュワーブ,
アンジー グレース イー,
アーノン ローゼンタール,
Original Assignee
アレクトル エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクトル エルエルシー filed Critical アレクトル エルエルシー
Publication of JP2022542964A publication Critical patent/JP2022542964A/ja
Publication of JP2022542964A5 publication Critical patent/JP2022542964A5/ja
Priority to JP2024228136A priority Critical patent/JP2025060826A/ja
Application granted granted Critical
Publication of JP7612658B2 publication Critical patent/JP7612658B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022506146A 2019-07-31 2020-07-30 抗ms4a4a抗体、及びその使用方法 Active JP7612658B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024228136A JP2025060826A (ja) 2019-07-31 2024-12-25 抗ms4a4a抗体、及びその使用方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962881187P 2019-07-31 2019-07-31
US62/881,187 2019-07-31
US201962892467P 2019-08-27 2019-08-27
US62/892,467 2019-08-27
US201962947449P 2019-12-12 2019-12-12
US62/947,449 2019-12-12
US202062960606P 2020-01-13 2020-01-13
US62/960,606 2020-01-13
US202063057142P 2020-07-27 2020-07-27
US63/057,142 2020-07-27
PCT/US2020/044335 WO2021022083A2 (en) 2019-07-31 2020-07-30 Anti-ms4a4a antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024228136A Division JP2025060826A (ja) 2019-07-31 2024-12-25 抗ms4a4a抗体、及びその使用方法

Publications (3)

Publication Number Publication Date
JP2022542964A JP2022542964A (ja) 2022-10-07
JP2022542964A5 JP2022542964A5 (cg-RX-API-DMAC7.html) 2023-08-07
JP7612658B2 true JP7612658B2 (ja) 2025-01-14

Family

ID=72139691

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506146A Active JP7612658B2 (ja) 2019-07-31 2020-07-30 抗ms4a4a抗体、及びその使用方法
JP2024228136A Withdrawn JP2025060826A (ja) 2019-07-31 2024-12-25 抗ms4a4a抗体、及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024228136A Withdrawn JP2025060826A (ja) 2019-07-31 2024-12-25 抗ms4a4a抗体、及びその使用方法

Country Status (20)

Country Link
US (2) US11667699B2 (cg-RX-API-DMAC7.html)
EP (1) EP4003519A2 (cg-RX-API-DMAC7.html)
JP (2) JP7612658B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220058540A (cg-RX-API-DMAC7.html)
CN (2) CN119954954A (cg-RX-API-DMAC7.html)
AU (1) AU2020321969A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001733A2 (cg-RX-API-DMAC7.html)
CA (1) CA3145885A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022000230A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000832A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220078A (cg-RX-API-DMAC7.html)
EC (1) ECSP22015044A (cg-RX-API-DMAC7.html)
IL (1) IL289952A (cg-RX-API-DMAC7.html)
MX (1) MX2022001260A (cg-RX-API-DMAC7.html)
MY (1) MY208743A (cg-RX-API-DMAC7.html)
NZ (1) NZ785401A (cg-RX-API-DMAC7.html)
PE (1) PE20220487A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550239A1 (cg-RX-API-DMAC7.html)
TW (2) TW202519558A (cg-RX-API-DMAC7.html)
WO (1) WO2021022083A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3746476A1 (en) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
EP3746484A4 (en) 2018-01-31 2021-11-17 Alector LLC ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF
PH12022550239A1 (en) 2019-07-31 2022-12-19 Alector Llc Anti-ms4a4a antibodies and methods of use thereof
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
AU2023314795A1 (en) * 2022-07-29 2025-03-06 Alector Llc Anti-gpnmb antibodies and methods of use thereof
CN119497721A (zh) * 2022-07-29 2025-02-21 艾莱克特有限责任公司 转铁蛋白受体抗原结合结构域及其用途
WO2024086796A1 (en) 2022-10-20 2024-04-25 Alector Llc Anti-ms4a4a antibodies with amyloid-beta therapies
CN116789821A (zh) * 2022-12-07 2023-09-22 南方医科大学南方医院 Ms4a4a作为靶点或抗ms4a4a单克隆抗体在制备治疗结直肠癌的药物中的应用
AU2024370996A1 (en) 2023-10-30 2026-05-14 Regeneron Pharmaceuticals, Inc. Treatment of myeloid cell dysfunction with membrane spanning 4-domains a6a (ms4a6a) inhibitors

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
AU2002251692A1 (en) 2000-12-08 2002-08-19 Duke University Identification of novel ms4a gene family members expressed by hematopoietic cells
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
GB0324888D0 (en) * 2003-10-24 2003-11-26 Novartis Ag Organic compounds
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
AU2005255024C1 (en) 2004-06-14 2010-09-09 The Board Of Trustees Of The University Of Illinois Antibodies binding to CD34+/CD36+ fetal but not to adult cells
CN101001879A (zh) * 2004-06-14 2007-07-18 伊利诺伊大学董事会 与胎儿而非成体cd34+/cd36+细胞结合的抗体
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
HUE066795T2 (hu) 2006-03-15 2024-09-28 Alexion Pharma Inc Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
WO2008029290A2 (en) * 2006-09-07 2008-03-13 Universidad De Salamanca Identification of cancer stem cells using genetic markers
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2108701A1 (en) * 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
WO2010059543A1 (en) * 2008-11-20 2010-05-27 Merck Sharp & Dohme Corp. Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
CN104774264B (zh) 2014-01-15 2018-09-14 上海易乐生物技术有限公司 抗人proBDNF单克隆抗体及其在疼痛中的作用
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN115960235A (zh) * 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
US20190321443A1 (en) 2016-02-16 2019-10-24 President And Fellows Of Harvard College Modulators of MS4A activity
CN105759057A (zh) * 2016-04-12 2016-07-13 上海凯璟生物科技有限公司 一种检测阿尔兹海默综合症ms4a6a的干式免疫荧光试剂盒和制备方法
MY205541A (en) * 2017-08-03 2024-10-25 Alector Llc Anti-cd33 antibodies and methods of use thereof
EP3746476A1 (en) 2018-01-31 2020-12-09 Alector LLC Anti-ms4a4a antibodies and methods of use thereof
EP3746484A4 (en) 2018-01-31 2021-11-17 Alector LLC ANTI-MS4A6A ANTIBODY AND METHOD OF USING THEREOF
PH12022550239A1 (en) 2019-07-31 2022-12-19 Alector Llc Anti-ms4a4a antibodies and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Immunology and Cell Biology,2015年,pp.1-13,DOI: 10.1038/icb.2015.48
Immunology and Cell Biology,2017年,Vol.95,pp.611-619,doi:10.1038/icb.2017.18
membrane-spanning 4-domains subfamily A member 4A isoform 1 [Homo sapiens],NCBI Reference Sequence: NP_683876.1, NCBI,2019年05月02日,pp.1-3,https://www.ncbi.nlm.nih.gov/protein/23110995?sat=47&satkey=82929062 [検索日:2024/07/01]

Also Published As

Publication number Publication date
CN114341181B (zh) 2025-01-07
IL289952A (en) 2022-03-01
JP2025060826A (ja) 2025-04-10
CR20220078A (es) 2022-06-24
JP2022542964A (ja) 2022-10-07
KR20220058540A (ko) 2022-05-09
WO2021022083A3 (en) 2021-03-11
PH12022550239A1 (en) 2022-12-19
US20240076362A1 (en) 2024-03-07
TWI874431B (zh) 2025-03-01
CL2022000230A1 (es) 2022-10-07
US20210079074A1 (en) 2021-03-18
ECSP22015044A (es) 2022-03-31
CN119954954A (zh) 2025-05-09
EP4003519A2 (en) 2022-06-01
MY208743A (en) 2025-05-27
PE20220487A1 (es) 2022-04-04
TW202120547A (zh) 2021-06-01
AU2020321969A1 (en) 2022-03-17
MX2022001260A (es) 2022-04-18
CN114341181A (zh) 2022-04-12
US11667699B2 (en) 2023-06-06
BR112022001733A2 (pt) 2022-06-28
CA3145885A1 (en) 2021-02-04
WO2021022083A2 (en) 2021-02-04
TW202519558A (zh) 2025-05-16
NZ785401A (en) 2025-11-28
CO2022000832A2 (es) 2022-04-29

Similar Documents

Publication Publication Date Title
JP7486636B2 (ja) 抗ms4a4a抗体及びその使用方法
US20240076362A1 (en) Anti-ms4a4a antibodies and methods of use thereof
US20230303681A1 (en) Anti-tmem106b antibodies and methods of use thereof
US12215149B2 (en) Anti-MS4A6A antibodies and methods of use thereof
WO2024086796A1 (en) Anti-ms4a4a antibodies with amyloid-beta therapies
US20240174746A1 (en) Anti-tmem106b antibodies and methods of use thereof
HK40063237A (en) Anti-ms4a4a antibodies and methods of use thereof
HK40036037A (en) Anti-ms4a6a antibodies and methods of use thereof
HK40034438A (zh) 抗ms4a4a抗体及其使用方法
HK40036920A (en) Anti-tmem106b antibodies and methods of use thereof

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220907

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230728

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241225

R150 Certificate of patent or registration of utility model

Ref document number: 7612658

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150